Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

OBJECTIVES: To evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis (RA), and maintenance of remission following the rapid withdrawal of all RA treatment. METHODS: In the Assessing Very Earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Burmester, Gerd R, Bykerk, Vivian P, Combe, Bernard G, Furst, Daniel E, Barré, Emilie, Karyekar, Chetan S, Wong, Dennis A, Huizinga, Tom W J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283672/
https://www.ncbi.nlm.nih.gov/pubmed/25367713
http://dx.doi.org/10.1136/annrheumdis-2014-206106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283672/
https://www.ncbi.nlm.nih.gov/pubmed/25367713
http://dx.doi.org/10.1136/annrheumdis-2014-206106

Ejemplares similares